Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment

Journal Article · Sun Apr 15 04:00:00 EDT 2018 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/J.IJROBP.2018.01.001· OSTI ID:23082767

Kong, Xiao-Tang ^[1]; Nguyen, Nhung T.; Choi, Yoon J. ^[1]; Zhang, Guicheng ^[2]; Nguyen, HuyTram N. ^[1]; others, and

---

1. Department of Neurology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles (United States)
2. School of Public Health, Xinxiang Medical University, Xinxiang, China, and Curtin University, Perth, Western Australia (Australia)

To assess the safety and efficacy of upfront treatment using bortezomib combined with standard radiation therapy (RT) and temozolomide (TMZ), followed by adjuvant bortezomib and TMZ for ≤24 cycles, in patients with newly diagnosed glioblastoma multiforme (GBM).

• OSTI ID: 23082767
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 5 Vol. 100; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
DIAGNOSIS
GLIOMAS
PATIENTS
RADIOTHERAPY
SAFETY